These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23639540)

  • 1. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
    Engers DW; Frist AY; Lindsley CW; Hong CC; Hopkins CR
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3248-52. PubMed ID: 23639540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
    Williams E; Bullock AN
    Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
    Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
    Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
    ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.
    Cuny GD; Yu PB; Laha JK; Xing X; Liu JF; Lai CS; Deng DY; Sachidanandan C; Bloch KD; Peterson RT
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4388-92. PubMed ID: 18621530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.
    Hao J; Ho JN; Lewis JA; Karim KA; Daniels RN; Gentry PR; Hopkins CR; Lindsley CW; Hong CC
    ACS Chem Biol; 2010 Feb; 5(2):245-53. PubMed ID: 20020776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
    Yamamoto H; Sakai N; Ohte S; Sato T; Sekimata K; Matsumoto T; Nakamura K; Watanabe H; Mishima-Tsumagari C; Tanaka A; Hashizume Y; Honma T; Katagiri T; Miyazono K; Tomoda H; Shirouzu M; Koyama H
    Bioorg Med Chem Lett; 2021 Apr; 38():127858. PubMed ID: 33609658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addressing species specific metabolism and solubility issues in a quinoline series of oral PDE4 inhibitors.
    Lunniss C; Eldred C; Aston N; Craven A; Gohil K; Judkins B; Keeling S; Ranshaw L; Robinson E; Shipley T; Trivedi N
    Bioorg Med Chem Lett; 2010 Jan; 20(1):137-40. PubMed ID: 19932963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone morphogenetic protein 2 regulates cell-cell communication by down-regulating connexin43 expression in luteinized human granulosa cells.
    Wu YT; Chang HM; Huang HF; Sheng JZ; Leung PC
    Mol Hum Reprod; 2017 Mar; 23(3):155-165. PubMed ID: 27986931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.
    Engers DW; Bollinger SR; Felts AS; Vadukoot AK; Williams CH; Blobaum AL; Lindsley CW; Hong CC; Hopkins CR
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127418. PubMed ID: 32750526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Pyrazolo[1,5-a]pyrimidines as Translocator Protein 18 kDa (TSPO) Ligands: Synthesis, in Vitro Biological Evaluation, [(18)F]-Labeling, and in Vivo Neuroinflammation PET Images.
    Damont A; Médran-Navarrete V; Cacheux F; Kuhnast B; Pottier G; Bernards N; Marguet F; Puech F; Boisgard R; Dollé F
    J Med Chem; 2015 Sep; 58(18):7449-64. PubMed ID: 26280386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 7-(aminoalkyl)pyrazolo[1,5-a]pyrimidine derivatives as cathepsin K inhibitors.
    Petek N; Štefane B; Novinec M; Svete J
    Bioorg Chem; 2019 Mar; 84():226-238. PubMed ID: 30502634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2.
    Němec V; Remeš M; Beňovský P; Böck MC; Šranková E; Wong JF; Cros J; Williams E; Tse LH; Smil D; Ensan D; Isaac MB; Al-Awar R; Gomolková R; Ursachi VC; Fafílek B; Kahounová Z; Víchová R; Vacek O; Berger BT; Wells CI; Corona CR; Vasta JD; Robers MB; Krejci P; Souček K; Bullock AN; Knapp S; Paruch K
    J Med Chem; 2024 Aug; 67(15):12632-12659. PubMed ID: 39023313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective synthesis of 1-substituted 4-chloropyrazolo[3,4-d]pyrimidines.
    Babu S; Morrill C; Almstead NG; Moon YC
    Org Lett; 2013 Apr; 15(8):1882-5. PubMed ID: 23574146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors.
    Fang Z; Wang TQ; Li H; Zhang G; Wu XA; Yang L; Peng YL; Zou J; Li LL; Xiang R; Yang SY
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3201-3204. PubMed ID: 28539219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.
    Scott JS; Brocklehurst KJ; Brown HS; Clarke DS; Coe H; Groombridge SD; Laber D; MacFaul PA; McKerrecher D; Schofield P
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3175-9. PubMed ID: 23628336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.